Theracos, Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, March 2011, Pages: 30

Theracos, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Theracos, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Theracos, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Theracos, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Theracos, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Theracos, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Theracos, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Theracos, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Theracos, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Theracos, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Theracos, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Theracos, Inc. Snapshot
Theracos, Inc. Overview
Key Information
Key Facts
Theracos, Inc. – Research and Development Overview
Key Therapeutic Areas
Theracos, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Theracos, Inc. – Pipeline Products Glance
Theracos, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Theracos, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Theracos, Inc. – Drug Profiles
EGT0001442
Product Description
Mechanism of Action
R&D Progress
THR-0921
Product Description
Mechanism of Action
R&D Progress
THR-4109
Product Description
Mechanism of Action
R&D Progress
EGT0001474
Product Description
Mechanism of Action
R&D Progress
Sertraline + Telenzepine
Product Description
Mechanism of Action
R&D Progress
THR-0940
Product Description
Mechanism of Action
R&D Progress
THR-090717
Product Description
Mechanism of Action
R&D Progress
THR-4218
Product Description
Mechanism of Action
R&D Progress
Theracos, Inc. – Pipeline Analysis
Theracos, Inc. – Pipeline Products by Therapeutic Class
Theracos, Inc. - Pipeline Products By Target
Theracos, Inc. – Pipeline Products by Route of Administration
Theracos, Inc. – Pipeline Products by Molecule Type
Theracos, Inc. – Recent Pipeline Updates
Theracos, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Aug 31, 2007: Theracos initiates Phase II clinical trial to evaluate the safety
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Theracos, Inc. – Pipeline by Therapy Area and Indication, 2011
Theracos, Inc. – Pipeline by Stage of Development, 2011
Theracos, Inc. – Monotherapy Products in Pipeline, 2011
Theracos, Inc. – Combination Treatment Modalities in Pipeline, 2011
Theracos, Inc. - Phase II, 2011
Theracos, Inc. - Phase I, 2011
Theracos, Inc. - Pipeline By Therapeutic Class, 2011
Theracos, Inc. - Pipeline By Target, 2011
Theracos, Inc. – Pipeline By Route of Administration, 2011
Theracos, Inc. – Pipeline By Molecule Type, 2011
Theracos, Inc. – Recent Pipeline Updates, 2011

List of Figures
Theracos, Inc. – Pipeline by Therapy Area and Indication, 2011
Theracos, Inc. – Pipeline by Stage of Development, 2011
Theracos, Inc. – Monotherapy Products in Pipeline, 2011
Theracos, Inc. – Combination Treatment Modalities in Pipeline, 2011
Theracos, Inc. – Pipeline By Therapeutic Class, 2011
Theracos, Inc. - Pipeline By Target, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• eBay - Strong Execution
• Insight into Samsung Electronics' Notebook PC Business Model
• Accenture - Profile - US
• Dell - Profile - US